Inhibitory Effects Of Matrine Combined With Antineoplastic On Proliferation Of K562 Cells

Background: Successive studies have demonstrated gradually improved outcome for patients with leukemia from 5year event free survival of 30-50% in earlier trials to 80% in the most recently completed study. These improvements have come about from a wide use of standardized therapy focusing on precise risk classification amalgamating clinical, laboratory and cytogenetic data. However, a small group of leukemia patients still fare poorly despite intensification of conventional treatment. The main obstacles to are: the individual different response to the treatment, early relapse within the first 12 months of therapy. Survivors of the leukemia patients usually experience a variety of late effects including anthracycline cardiactoxicity, neurocognitive and psychological problems. Continue improvements in outcome will come from further refinements in risk classification and the development of more specific therapies targeting drug resistance and leukaemogenesis mechanisms.Matrine (Mat) is a kind of alkaloid, coming from leguminous plants...